Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.32M Buy
10,983
+779
+8% +$89.9K 0.14% 96
2025
Q4
$1.07M Buy
10,204
+425
+4% +$39.9K 0.12% 101
2025
Q3
$821K Buy
9,779
+304
+3% +$25K 0.11% 117
2025
Q2
$750K Sell
9,475
-1,479
-14% -$118K 0.11% 120
2025
Q1
$983K Sell
10,954
-71
-0.6% -$6.63K 0.15% 99
2024
Q4
$1.1M Buy
11,025
+422
+4% +$43.5K 0.17% 85
2024
Q3
$1.2M Sell
10,603
-69
-0.6% -$8.2K 0.2% 81
2024
Q2
$1.32M Sell
10,672
-355
-3% -$45.7K 0.24% 71
2024
Q1
$1.46M Buy
11,027
+90
+0.8% +$11.1K 0.26% 66
2023
Q4
$1.19M Sell
10,937
-134
-1% -$13.9K 0.23% 72
2023
Q3
$1.14M Buy
11,071
+6
+0.1% +$647 0.26% 71
2023
Q2
$1.28M Buy
11,065
+800
+8% +$90.8K 0.27% 63
2023
Q1
$1.09M Sell
10,265
-52
-0.5% -$5.61K 0.24% 66
2022
Q4
$1.14M Buy
10,317
+359
+4% +$36.7K 0.28% 62
2022
Q3
$858K Buy
9,958
+2,148
+28% +$192K 0.23% 74
2022
Q2
$712K Buy
7,810
+291
+4% +$25.8K 0.19% 85
2022
Q1
$617K Buy
7,519
+2,016
+37% +$159K 0.15% 90
2021
Q4
$422K Buy
5,503
+12
+0.2% +$956 0.11% 109
2021
Q3
$455K Sell
5,491
-1,888
-26% -$144K 0.33% 52
2021
Q2
$574K Buy
7,379
+513
+7% +$38.2K 0.16% 85
2021
Q1
$505K Buy
6,866
+998
+17% +$73.6K 0.19% 74
2020
Q4
$458K Buy
5,868
+113
+2% +$8.64K 0.28% 59
2020
Q3
$455K Buy
5,755
+693
+14% +$54.3K 0.33% 52
2020
Q2
$373K Buy
5,062
+520
+11% +$39.1K 0.31% 55
2020
Q1
$333K Buy
4,542
+464
+11% +$36.5K 0.34% 55
2019
Q4
$354K Buy
+4,078
New +$335K 0.33% 54

Other funds holding MRK

CVA Family Office's MRK Position: Q1 2026 in Review

CVA Family Office increased its Merck (MRK) stake by 7.6% in Q1 2026, buying an estimated $89.9K and bringing the position to 10,983 shares worth $1.32M. The position accounts for 0.14% of the portfolio, ranked #96.

CVA Family Office first reported a position in MRK in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.46M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • CVA Family Office held 10,983 shares of Merck worth $1.32M as of Q1 2026.
  • CVA Family Office bought 779 Merck shares in Q1 2026, an estimated $89.9K.
  • Merck made up 0.14% of CVA Family Office's portfolio in Q1 2026, its #96 holding.
  • CVA Family Office first reported a position in Merck in Q4 2019 and has held it in 26 quarters since.
  • CVA Family Office's Merck position peaked at $1.46M in Q1 2024.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.